NASDAQ:GLYC - GlycoMimetics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.00
  • Forecasted Upside: 338.60 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.42
▼ -0.06 (-1.72%)
1 month | 3 months | 12 months
Get New GlycoMimetics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLYC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLYC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$15.00
▲ +338.60% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for GlycoMimetics in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 338.60% upside from the last price of $3.42.
Buy
The current consensus among 3 contributing investment analysts is to buy stock in GlycoMimetics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/4/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/3/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2020Roth CapitalBoost Price TargetPositive ➝ Buy$9.00 ➝ $15.00Medium
i
7/31/2020HC WainwrightLower Price TargetBuy$16.00 ➝ $15.00Medium
i
5/1/2020HC WainwrightReiterated RatingBuy$16.00High
i
3/27/2020CowenInitiated CoverageBuyLow
i
Rating by Boris Peaker at Cowen Inc
3/2/2020HC WainwrightLower Price TargetBuy$18.00 ➝ $16.00High
i
11/21/2019Roth CapitalLower Price Target$12.00 ➝ $9.00High
i
Rating by Z. Jallah at Roth Capital
11/14/2019Roth CapitalInitiated CoverageBuy$12.00 ➝ $12.00Medium
i
Rating by Z. Jallah at Roth Capital
11/8/2019HC WainwrightReiterated RatingBuy$18.00High
i
11/7/2019Piper Jaffray CompaniesReiterated RatingNeutral$6.00 ➝ $5.00High
i
Rating by Danielle Brill at Piper Jaffray Companies
8/5/2019HC WainwrightLower Price TargetBuy$23.00 ➝ $18.00High
i
8/5/2019Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
i
8/5/2019SunTrust BanksDowngradeBuy ➝ Hold$23.00 ➝ $5.00High
i
8/4/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$20.00 ➝ $6.00High
i
5/3/2019CowenReiterated RatingBuyMedium
i
4/12/2019HC WainwrightReiterated RatingBuy$23.00Low
i
Rating by E. White at HC Wainwright
4/12/2019Piper Jaffray CompaniesInitiated CoverageOverweight$20.00High
i
12/18/2018HC WainwrightInitiated CoverageBuy ➝ Buy$24.00Low
i
Rating by E. White at HC Wainwright
11/5/2018Roth CapitalSet Price TargetBuy$35.00High
i
Rating by Jotin Marango at Roth Capital
8/13/2018CowenReiterated RatingBuyMedium
i
8/12/2018Stifel NicolausReiterated RatingBuy$24.00Medium
i
3/7/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$23.00 ➝ $25.00Medium
i
2/8/2018Roth CapitalSet Price TargetBuy$35.00Medium
i
Rating by Jotin Marango at Roth Capital
12/20/2017Jefferies Financial GroupReiterated RatingBuy$21.00Medium
i
12/14/2017Stifel NicolausReiterated RatingBuy$23.00Medium
i
12/12/2017SunTrust BanksBoost Price TargetBuy$32.00High
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
12/6/2017CowenReiterated RatingBuyLow
i
10/26/2017Jefferies Financial GroupReiterated RatingBuy$16.00N/A
i
10/23/2017Roth CapitalInitiated CoverageBuy$25.00N/A
i
Rating by J. Marango at Roth Capital
10/4/2017SunTrust BanksReiterated RatingBuy$21.00N/A
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
8/7/2017SunTrust BanksSet Price TargetBuy$21.00Low
i
8/4/2017Stifel NicolausReiterated RatingBuy$13.00 ➝ $17.00Low
i
6/6/2017Stifel NicolausReiterated RatingBuy$13.00High
i
6/6/2017Jefferies Financial GroupLower Price TargetBuy$16.00 ➝ $9.00High
i
5/28/2017CowenReiterated RatingOutperformLow
i
5/19/2017Canaccord GenuityReiterated RatingBuy$12.00High
i
Rating by John Newman at Canaccord Genuity
5/9/2017CowenReiterated RatingBuyLow
i
3/1/2017Canaccord GenuitySet Price TargetBuy$12.00N/A
i
Rating by John Newman at Canaccord Genuity
12/6/2016Canaccord GenuitySet Price TargetBuy$12.00N/A
i
Rating by John Newman at Canaccord Genuity
11/30/2016SunTrust BanksReiterated RatingBuyN/A
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
8/15/2016CowenInitiated CoverageOutperformN/A
i
8/7/2016Canaccord GenuityReiterated RatingBuy$12.00N/A
i
Rating by John Newman at Canaccord Genuity
8/5/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
8/5/2016Stifel NicolausBoost Price TargetBuy$13.00 ➝ $15.00N/A
i
7/26/2016SunTrust BanksInitiated CoverageBuy$16.00N/A
i
5/4/2016Canaccord GenuityReiterated RatingBuy$12.00N/A
i
Rating by John Newman at Canaccord Genuity
3/1/2016Jefferies Financial GroupLower Price TargetBuy$14.00 ➝ $11.00N/A
i
3/1/2016Canaccord GenuityReiterated RatingBuy$12.00N/A
i
Rating by John Newman at Canaccord Genuity
(Data available from 2/25/2016 forward)
GlycoMimetics logo
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist, which has completed Phase III clinical trial for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $3.42
$3.33
$3.50

50 Day Range

MA: $3.87
$3.50
$4.22

52 Week Range

Now: $3.42
$1.82
$5.19

Volume

45,822 shs

Average Volume

818,240 shs

Market Capitalization

$163.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.46

Frequently Asked Questions

What sell-side analysts currently cover shares of GlycoMimetics?

The following Wall Street sell-side analysts have issued research reports on GlycoMimetics in the last twelve months: Cowen Inc, HC Wainwright, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for GLYC.

What is the current price target for GlycoMimetics?

2 Wall Street analysts have set twelve-month price targets for GlycoMimetics in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 331.0%. Roth Capital has the highest price target set, predicting GLYC will reach $15.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $15.00 for GlycoMimetics in the next year.
View the latest price targets for GLYC.

What is the current consensus analyst rating for GlycoMimetics?

GlycoMimetics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GLYC will outperform the market and that investors should add to their positions of GlycoMimetics.
View the latest ratings for GLYC.

What other companies compete with GlycoMimetics?

How do I contact GlycoMimetics' investor relations team?

GlycoMimetics' physical mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company's listed phone number is 240-243-1201 and its investor relations email address is [email protected] The official website for GlycoMimetics is www.glycomimetics.com.